101 related articles for article (PubMed ID: 28870543)
1. Development and comprehensive comparison of two on-line capillary electrophoretic methods for β-secretase inhibitor screening.
Řemínek R; Slezáčková L; Schejbal J; Glatz Z
J Chromatogr A; 2017 Oct; 1518():89-96. PubMed ID: 28870543
[TBL] [Abstract][Full Text] [Related]
2. Screening of Beta-Secretase Inhibitors by Capillary Electrophoresis-Mass Spectrometry.
Schejbal J; Řemínek R; Glatz Z
Methods Mol Biol; 2020; 2089():147-157. PubMed ID: 31773652
[TBL] [Abstract][Full Text] [Related]
3. Capillary electrophoresis integrated immobilized enzyme reactor for kinetic and inhibition assays of β-secretase as the Alzheimer's disease drug target.
Schejbal J; Šefraná Š; Řemínek R; Glatz Z
J Sep Sci; 2019 Mar; 42(5):1067-1076. PubMed ID: 30663871
[TBL] [Abstract][Full Text] [Related]
4. A capillary electrophoresis-mass spectrometry based method for the screening of β-secretase inhibitors as potential Alzheimer's disease therapeutics.
Schejbal J; Slezáčková L; Řemínek R; Glatz Z
J Chromatogr A; 2017 Mar; 1487():235-241. PubMed ID: 28153449
[TBL] [Abstract][Full Text] [Related]
5. A microfluidics-based mobility shift assay to identify new inhibitors of β-secretase for Alzheimer's disease.
Liu R; Liu YC; Meng J; Zhu H; Zhang X
Anal Bioanal Chem; 2017 Nov; 409(28):6635-6642. PubMed ID: 28889204
[TBL] [Abstract][Full Text] [Related]
6. An in-line capillary electrophoresis assay for the high-throughput screening of histone deacetylase inhibitors.
Li Y; Fang H; Hou Z; Sang L; Yang X
J Chromatogr A; 2019 Apr; 1591():171-177. PubMed ID: 30665742
[TBL] [Abstract][Full Text] [Related]
7. A label-free MALDI TOF MS-based method for studying the kinetics and inhibitor screening of the Alzheimer's disease drug target β-secretase.
Machálková M; Schejbal J; Glatz Z; Preisler J
Anal Bioanal Chem; 2018 Nov; 410(28):7441-7448. PubMed ID: 30218128
[TBL] [Abstract][Full Text] [Related]
8. Inkjet printing-based β-secretase fluorescence resonance energy transfer (FRET) assay for screening of potential β-secretase inhibitors of Alzheimer's disease.
Lee J; Samson AAS; Song JM
Anal Chim Acta; 2018 Aug; 1022():89-95. PubMed ID: 29729742
[TBL] [Abstract][Full Text] [Related]
9. Multiwell fluorometric and colorimetric microassays for the evaluation of beta-secretase (BACE-1) inhibitors.
Mancini F; Naldi M; Cavrini V; Andrisano V
Anal Bioanal Chem; 2007 Jul; 388(5-6):1175-83. PubMed ID: 17541560
[TBL] [Abstract][Full Text] [Related]
10. Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease.
D'Onofrio G; Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Paroni G; Cascavilla L; Seripa D; Pilotto A
Expert Opin Drug Discov; 2012 Jan; 7(1):19-37. PubMed ID: 22468891
[TBL] [Abstract][Full Text] [Related]
11. The search for drug leads targeted to the beta-secretase: an example of the roles of computer assisted approaches in drug discovery.
Villaverde MC; González-Louro L; Sussman F
Curr Top Med Chem; 2007; 7(10):980-90. PubMed ID: 17508931
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic intervention for Alzheimer's disease with γ-secretase inhibitors: still a viable option?
Imbimbo BP; Panza F; Frisardi V; Solfrizzi V; D'Onofrio G; Logroscino G; Seripa D; Pilotto A
Expert Opin Investig Drugs; 2011 Mar; 20(3):325-41. PubMed ID: 21222550
[TBL] [Abstract][Full Text] [Related]
13. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.
Martone RL; Zhou H; Atchison K; Comery T; Xu JZ; Huang X; Gong X; Jin M; Kreft A; Harrison B; Mayer SC; Aschmies S; Gonzales C; Zaleska MM; Riddell DR; Wagner E; Lu P; Sun SC; Sonnenberg-Reines J; Oganesian A; Adkins K; Leach MW; Clarke DW; Huryn D; Abou-Gharbia M; Magolda R; Bard J; Frick G; Raje S; Forlow SB; Balliet C; Burczynski ME; Reinhart PH; Wan HI; Pangalos MN; Jacobsen JS
J Pharmacol Exp Ther; 2009 Nov; 331(2):598-608. PubMed ID: 19671883
[TBL] [Abstract][Full Text] [Related]
14. Advances in the identification of β-secretase inhibitors.
Hamada Y; Kiso Y
Expert Opin Drug Discov; 2013 Jun; 8(6):709-31. PubMed ID: 23565721
[TBL] [Abstract][Full Text] [Related]
15. Secretase inhibitors and modulators for Alzheimer's disease treatment.
Tomita T
Expert Rev Neurother; 2009 May; 9(5):661-79. PubMed ID: 19402777
[TBL] [Abstract][Full Text] [Related]
16. Alzheimer's amyloid precursor protein alpha-secretase is inhibited by hydroxamic acid-based zinc metalloprotease inhibitors: similarities to the angiotensin converting enzyme secretase.
Parvathy S; Hussain I; Karran EH; Turner AJ; Hooper NM
Biochemistry; 1998 Feb; 37(6):1680-5. PubMed ID: 9484239
[TBL] [Abstract][Full Text] [Related]
17. Specific Inhibition of β-Secretase Processing of the Alzheimer Disease Amyloid Precursor Protein.
Ben Halima S; Mishra S; Raja KMP; Willem M; Baici A; Simons K; Brüstle O; Koch P; Haass C; Caflisch A; Rajendran L
Cell Rep; 2016 Mar; 14(9):2127-2141. PubMed ID: 26923602
[TBL] [Abstract][Full Text] [Related]
18. Beta-secretase as a target for Alzheimer's disease drug discovery: an overview of in vitro methods for characterization of inhibitors.
Mancini F; De Simone A; Andrisano V
Anal Bioanal Chem; 2011 Jun; 400(7):1979-96. PubMed ID: 21503735
[TBL] [Abstract][Full Text] [Related]
19. γ-Secretase as a target for Alzheimer's disease.
Wolfe MS
Adv Pharmacol; 2012; 64():127-53. PubMed ID: 22840746
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and evaluation of tetrahydroquinoline and pyrrolidine sulfonamide carbamates as gamma-secretase inhibitors.
Guo T; Gu H; Hobbs DW; Rokosz LL; Stauffer TM; Jacob B; Clader JW
Bioorg Med Chem Lett; 2007 Jun; 17(11):3010-3. PubMed ID: 17418571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
